Rapid, Safe and Effective Vaccines for Global Health

Michael Artinger, PhD – CEO 

Dr. Artinger is an experienced life science professional, with decades of his career dedicated to creating new, life-saving therapeutics and vaccines. He is EVP and Managing Director of VIC Technology Venture Development, which creates and develops innovative life science companies based on technologies exclusively licensed from top research institutions worldwide. Examples of prior roles include high-impact positions at Sartorius, University of California, Decision Resources, and Genome Therapeutics. Dr. Artinger conducted his postdoctoral training at Harvard Medical School, and received his PhD and BA from the University of California where he was an NSF Undergraduate Research Fellow.

Calvin Goforth, PhD – Director

Goforth has extensive experience in start-up company development in founder, investor, board member, and executive roles. In these roles, he has raised tens of $millions in capital, helped bring several high value products from concept to market, and helped bring multiple companies to exit events. He received a BS in Aerospace Engineering with Highest Honors from the University of Texas at Austin. Early in his career, Dr. Goforth held positions at NASA (where he worked alternate semesters while pursuing his BS) and Rocketdyne, where he worked in the space shuttle main engine performance analysis group. He later received his PhD in Mechanical Engineering with a minor in Electrical Engineering from Stanford University. He then returned to his home state of Arkansas and took a position as an Assistant Professor in Mechanical Engineering at the University of Arkansas. There, he received the school’s Halliburton Outstanding Researcher Award in Mechanical Engineering for three straight years.

 Olivia Asfaha, PhD – Program Manager

Dr. Asfaha is a neuroscientist and biochemist with 9 years of experience investigating kinase signaling pathways underlying memory. She has published 13 peer-reviewed scientific papers and acquired 2 NIH National Research Service Awards (F31 and F32) as principal investigator.

Dr. Asfaha received her PhD in Pharmacology and Toxicology from the University of California, Davis. Now, in addition to her work with Neurexis, she studies CaMKII-dependent mechanisms as a Postdoctoral Fellow in the Department of Pharmacology at the University of Colorado, Anschutz Medical Campus.